Reports Q3 collaboration revenue $2.1M, consensus $1.13M. “The continued advancements of our programs and platform have positioned us as a potential industry- leading solutions provider for immuno-oncology and autoimmune disease,” said Daniel Passeri, CEO of Cue Biopharma. “Importantly, we believe the positive data from our ongoing clinical trials has placed us in a sound position to continue developing our platform for selective and targeted modulation of disease relevant T cells in broader applications across many cancers and autoimmune diseases.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CUE:
- Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
- Cue Biopharma presents data from Phase 1 trials of CUE-101
- Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
- Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Cue Biopharma completes patient enrollment in Phase 1b study of CUE-101
